Merck & Co. & Sanofi

Merck & Co.: Merck & Co. is a key player in the antibody therapeutics market, benefiting from the projected market growth.

Sanofi: Sanofi is a key player in the antibody therapeutics market, benefiting from the projected market growth.

Merck & Co.: Developer and manufacturer of Lipfendra; approval boosts its cardiovascular pipeline and revenue prospects.

Sanofi: Co-marketer of Praluent; faces similar competitive pressure.

Merck & Co.: Merck & Co., a hepatitis B vaccine maker, expressed deep concern over the ACIP's vote, and its shares closed down 1.2% on Friday.

Sanofi: Sanofi, a hepatitis B vaccine maker, defended its products as safe, and its U.S.-listed shares ended up 1.3%.

Merck & Co.: Merck's Lipfendra, the first FDA-approved PCSK9 pill, competes with Scribe's STX-1150. Scribe's epigenetic approach may differentiate it.

Sanofi: Sanofi participated in a concurrent private placement, purchasing 500,000 shares for $7.5 million, and has a prior $1.5 billion research collaboration with Scribe. This deepens Sanofi's strategic involvement in gene editing and cardiovascular therapies.

Merck & Co.: Merck acquired Cubist Pharmaceuticals.

Sanofi: Patrick Vink started his career at Sanofi.

Merck & Co.: Merck & Co. struck a deal to cut prices, committing to sell its diabetes drugs Januvia, Janumet, and Janumet XR at 70% off list prices directly to US consumers and pledging $70 billion in US R&D and manufacturing investments.